drugset
drugset / Trial / NCT02657785

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

NCT02657785 ↗

Phase 2/3 Recruiting 100 enrolled Navy General Hospital, Beijing
NaSingle-groupOpen-labelTreatment

Summary

This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.

Timeline

Start
2010-09
Primary completion
2028-12
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 50 mg Intrathecal
Subject Cytarabine Small molecule 1000 mg/m2 Intrathecal
Subject Dexamethasone Small molecule 5 mg Intrathecal
Subject Dexamethasone Small molecule 100 mg/m2 Intrathecal
Subject Idarubicin Small molecule 10 mg/m2 —
Subject Methotrexate Small molecule 15 mg Intrathecal
Subject Methotrexate Small molecule 2000 mg/m2 Intrathecal
Subject Rituximab Monoclonal antibody 10 mg Intrathecal
Subject Rituximab Monoclonal antibody 375 mg/m2 Intrathecal

Indications

primary central nervous system lymphoma